KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Non-Current Deffered Revenue (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $12.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue changed N/A year-over-year to $12.2 million, compared with a TTM value of $12.2 million through Sep 2025, changed N/A, and an annual FY2024 reading of $1.7 million, changed N/A over the prior year.
  • Non-Current Deffered Revenue was $12.2 million for Q3 2025 at Aurinia Pharmaceuticals, down from $12.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $12.4 million in Q1 2025 and bottomed at $1.7 million in Q4 2024.